A Surprise About Minority and Majority Attitudes Regarding Clinical Trials and Its Relationship to Prostate Cancer Survivors Willingness to Participate in Clinical Trials

It is commonly known that our current clinical trials struggle to enroll adequate numbers of minority men. Our inability to enroll a cross section of men that truly reflects the general population in prostate cancer clinical trials means that our results might not accurately reflect the best information for a minority man. The lack of [...]

The Really Big Question We all Ask, Will I Die from Prostate Cancer?

Because of the large amount of prostate cancer screening there has been a major shift in initial staging in prostate cancer  in western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%.  Despite this very significant drop in late stage diagnoses prostate cancer is [...]

Adjuvant Radiotherapy Benefits Survival in Subsets of Men With Node-Positive Prostate Cancer

In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy)  enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]

Avoiding Increased Colon Cancer Risk Created By Errors Made in a Colonoscopy

Having been diagnosed with prostate cancer does not make you immune to developing another cancer. Look specifically at me; I have now been diagnosed with five different, primary cancers. Not only do we remain susceptible to developing another, unrelated primary cancer, we also are at an increased risk of developing a secondary cancer that is [...]

Increased Risks for Cardiovascular Events in Men with Prostate Cancer on GnRH Agonist Therapy

Traditional hormone therapy usually consists of two types of drugs; GnRH agonists (like Lupron and Zoladex) and antiandrogens (Casodex). Although they both are drugs that manipulate the hormone system their modes of action are different. GnRH agonists block the production of the male hormone testosterone while the antiandrogen drug blocks the ability of the prostate [...]

Go to Top